SG11201607368XA - Vaccine delivery systems using yeast cell wall particles - Google Patents

Vaccine delivery systems using yeast cell wall particles

Info

Publication number: SG11201607368XA
Authority: SG; Singapore
Prior art keywords: cell wall; delivery systems; yeast cell; vaccine delivery; wall particles
Prior art date: 2014-03-05

Application number

SG11201607368XA

Other languages

English (en)

Inventor

Thomas E Wagner

Original Assignee

Orbis Health Solutions Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-05

Filing date

2015-03-04

Publication date

2016-10-28

2015-03-04 Application filed by Orbis Health Solutions Llc filed Critical Orbis Health Solutions Llc

2016-10-28 Publication of SG11201607368XA publication Critical patent/SG11201607368XA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Oncology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Botany (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11201607368XA 2014-03-05 2015-03-04 Vaccine delivery systems using yeast cell wall particles SG11201607368XA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461948503P	2014-03-05	2014-03-05
US201462060124P	2014-10-06	2014-10-06
PCT/US2015/018728 WO2015134606A1 (en)	2014-03-05	2015-03-04	Vaccine delivery systems using yeast cell wall particles

Publications (1)

Publication Number	Publication Date
SG11201607368XA true SG11201607368XA (en)	2016-10-28

Family

ID=54055837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201607368XA SG11201607368XA (en)	2014-03-05	2015-03-04	Vaccine delivery systems using yeast cell wall particles

Country Status (9)

Country	Link
US (6)	US10166195B2 (ja)
EP (2)	EP3932392A1 (ja)
JP (3)	JP6797022B2 (ja)
KR (1)	KR102060858B1 (ja)
CN (1)	CN106456532B (ja)
AU (3)	AU2015227226B2 (ja)
CA (2)	CA2941633C (ja)
SG (1)	SG11201607368XA (ja)
WO (1)	WO2015134606A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3932392A1 (en)	2014-03-05	2022-01-05	Orbis Health Solutions LLC	Vaccine delivery systems using yeast cell wall particles
US10434064B2 (en)	2014-06-04	2019-10-08	Exicure, Inc.	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
KR20180080178A (ko) *	2015-08-11	2018-07-11	오르비스 헬스 솔루션즈 엘엘씨	세균성 백신 및 바이러스성 백신 방법
CN107233298B (zh) *	2016-03-28	2021-01-22	复旦大学	一种促进蛋白多肽药物口服吸收的酵母细胞壁微粒制剂
CN113143977B (zh) *	2021-04-16	2022-04-05	苏州大学	酵母细胞壁纳米颗粒及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4454110A (en)	1982-05-24	1984-06-12	Forsyth Dental Infirmary For Children	Self-gelling liquid composition for topical application in the oral cavity
US4563351A (en)	1983-08-01	1986-01-07	Forsyth Dental Infirmary For Children	Self-gelling therapeutic compositions for topical application
US5032401A (en)	1989-06-15	1991-07-16	Alpha Beta Technology	Glucan drug delivery system and adjuvant
US5340740A (en)	1992-05-15	1994-08-23	North Carolina State University	Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
JP3272891B2 (ja)	1994-11-22	2002-04-08	カネボウ株式会社	入浴剤
WO1999030629A1 (en)	1997-12-17	1999-06-24	Hemodynamics, Inc.	Sealing media for surgery and wound closure
US20050158856A1 (en)	1999-04-20	2005-07-21	Edelson Richard L.	Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US6342203B2 (en)	1999-10-27	2002-01-29	Dakota Dental Development, Inc.	Compositions for dentistry comprising an oil, to repair, restore, adhere to, or protect the surface of a tooth
AU2002225681A1 (en)	2000-11-15	2002-05-27	Globe Immune, Inc.	Yeast-dentritic cell vaccines and uses thereof
JP4313039B2 (ja)	2001-01-18	2009-08-12	ニューキャッスルユニバーシティベンチャーズリミティド	共有結合した膜貫通タンパク質によるバイオセンサー
CA2459713C (en)	2001-09-06	2015-08-18	Northwest Biotherapeutics, Inc.	Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
AU2003258181A1 (en)	2002-08-13	2004-02-25	University Of Louisville Research Foundation Inc.	Methods of using beta glucan as a radioprotective agent
EP1539194A4 (en)	2002-09-04	2007-06-13	Univ Louisville Res Found	ANTICANCER THERAPY IN WHICH BETA GLUCAN AND ANTIBODIES ARE USED
US20060165700A1 (en)	2002-09-04	2006-07-27	Ostroff Gary R	Cancer therapy using whole glucan particles and antibodies
US7943179B2 (en)	2003-09-23	2011-05-17	Massachusetts Institute Of Technology	pH triggerable polymeric particles
MXPA06013420A (es)	2004-05-20	2007-03-01	Eden Research Plc	Composiciones que contienen una particula hueca de glucano o una particula de pared celular que encapsula un componente de terpeno, metodos para elaborar y usar las mismas.
US8007814B2 (en)	2004-06-16	2011-08-30	University Of Massachusetts	Therapy for lysosomal enzyme deficiencies
US7740861B2 (en)	2004-06-16	2010-06-22	University Of Massachusetts	Drug delivery product and methods
CN102614510A (zh)	2004-10-18	2012-08-01	全球免疫股份有限公司	基于酵母的对慢性丙型肝炎感染的治疗
EP1814981A4 (en)	2004-10-25	2009-09-30	Baylor Res Inst	HEAT-SHOCK-TREATED MELANOMA CELLS LOAD DENDRITICAL CELLS
JP5489462B2 (ja)	2005-10-24	2014-05-14	ユニバーシティオブマサチューセッツ	骨病状の遺伝子治療のための組成物およびそれらの使用法
ES2848707T3 (es)	2005-11-30	2021-08-11	Eden Research Plc	Cápsulas insecticidas que contienen timol y métodos de fabricación y uso de las mismas
CN103589684A (zh)	2005-12-08	2014-02-19	西北生物治疗药物公司	用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法
JP5198290B2 (ja)	2006-02-02	2013-05-15	グローブイミューン，インコーポレイテッド	免疫反応を誘発する酵母ベースワクチン
US20080167268A1 (en)	2006-09-01	2008-07-10	Jun Yan	Particulate beta-glucan compositions for regulating dendritic cells
US20100111985A1 (en)	2007-04-25	2010-05-06	Orbis Health Solutions, Llc	Vaccine compositions and methods of use
US8389485B2 (en)	2007-10-29	2013-03-05	University Of Massachusetts	Encapsulated nanoparticles for nucleic acid delivery
JP5690143B2 (ja)	2008-02-13	2015-03-25	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	持続的細胞プログラミング装置
US8728465B2 (en)	2008-06-17	2014-05-20	Cedars-Sinai Medical Center	Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
EP2496265A1 (en)	2009-11-02	2012-09-12	Orbis Health Solutions LLC	Vaccine compositions and methods of use
WO2011088155A2 (en)	2010-01-12	2011-07-21	Purdue Research Foundation	Materials and methods for producing cell-surface directed and associated non-naturally occurring bioinorganic membranes and uses thereof
US8828944B2 (en)	2010-04-22	2014-09-09	Institut Gustave Roussy	Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
ES2614181T3 (es) *	2010-08-14	2017-05-30	University Of Massachusetts	Partícula de pared celular de levadura para suministro de nanopartículas direccionadas al receptor
RU2013132488A (ru)	2010-12-13	2015-01-20	Колгейт-Палмолив Компани	Пероральные композиции
US8926994B2 (en)	2011-12-07	2015-01-06	The Methodist Hospital Research Institute	Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US20140065173A1 (en)	2012-09-06	2014-03-06	Orbis Health Solutions Llc	Tumor lysate loaded particles
EP2931324B1 (en)	2012-12-12	2018-09-19	Orbis Health Solutions LLC	Compositions and methods for tissue regeneration
PH12013000256A1 (en)	2013-08-30	2015-03-09	Anacleto M Argayosa	Oral vaccine
EP3932392A1 (en) *	2014-03-05	2022-01-05	Orbis Health Solutions LLC	Vaccine delivery systems using yeast cell wall particles
US20180228885A1 (en)	2016-03-04	2018-08-16	Orbis Health Solutions Llc	Bacterial and viral vaccine strategy

2015
- 2015-03-04 EP EP21173240.9A patent/EP3932392A1/en not_active Withdrawn
- 2015-03-04 CA CA2941633A patent/CA2941633C/en active Active
- 2015-03-04 US US15/123,479 patent/US10166195B2/en active Active
- 2015-03-04 AU AU2015227226A patent/AU2015227226B2/en active Active
- 2015-03-04 CA CA3099413A patent/CA3099413A1/en active Pending
- 2015-03-04 EP EP15758254.5A patent/EP3113759B1/en active Active
- 2015-03-04 WO PCT/US2015/018728 patent/WO2015134606A1/en active Application Filing
- 2015-03-04 SG SG11201607368XA patent/SG11201607368XA/en unknown
- 2015-03-04 CN CN201580022772.8A patent/CN106456532B/zh active Active
- 2015-03-04 JP JP2016555517A patent/JP6797022B2/ja active Active
- 2015-03-04 KR KR1020167027182A patent/KR102060858B1/ko active IP Right Grant
2016
- 2016-08-31 US US15/252,999 patent/US20170007688A1/en not_active Abandoned
2018
- 2018-01-05 AU AU2018200092A patent/AU2018200092B2/en not_active Ceased
- 2018-12-20 US US16/227,468 patent/US10675249B2/en active Active
2019
- 2019-07-05 JP JP2019125837A patent/JP6914996B2/ja active Active
- 2019-11-06 US US16/676,395 patent/US11826476B2/en active Active
2020
- 2020-05-20 AU AU2020203274A patent/AU2020203274A1/en not_active Abandoned
- 2020-06-05 US US16/893,986 patent/US11179343B2/en active Active
2021
- 2021-07-14 JP JP2021116027A patent/JP7311560B2/ja active Active
- 2021-11-22 US US17/532,656 patent/US11759429B2/en active Active

Also Published As

Publication number	Publication date
US20220151943A1 (en)	2022-05-19
CA2941633A1 (en)	2015-09-11
US11179343B2 (en)	2021-11-23
AU2015227226B2 (en)	2017-10-05
BR112016020373A2 (pt)	2017-08-15
US20170065532A1 (en)	2017-03-09
US10675249B2 (en)	2020-06-09
US20200368172A1 (en)	2020-11-26
EP3113759A1 (en)	2017-01-11
EP3113759B1 (en)	2021-05-12
EP3932392A1 (en)	2022-01-05
AU2015227226A1 (en)	2016-10-27
EP3113759A4 (en)	2017-10-18
JP6797022B2 (ja)	2020-12-09
BR112016020373A8 (pt)	2021-06-29
AU2020203274A1 (en)	2020-06-11
AU2018200092A1 (en)	2018-01-25
US10166195B2 (en)	2019-01-01
CA2941633C (en)	2021-01-12
US11826476B2 (en)	2023-11-28
WO2015134606A1 (en)	2015-09-11
US20190240162A1 (en)	2019-08-08
JP7311560B2 (ja)	2023-07-19
AU2018200092B2 (en)	2020-02-27
KR20160132044A (ko)	2016-11-16
CA3099413A1 (en)	2015-09-11
JP6914996B2 (ja)	2021-08-04
JP2017507152A (ja)	2017-03-16
CN106456532B (zh)	2020-07-24
US20200069596A1 (en)	2020-03-05
JP2021169495A (ja)	2021-10-28
JP2019203004A (ja)	2019-11-28
CN106456532A (zh)	2017-02-22
US11759429B2 (en)	2023-09-19
KR102060858B1 (ko)	2019-12-30
US20170007688A1 (en)	2017-01-12

Publication	Publication Date	Title
EP3188843A4 (en)	2018-03-14	Electrostatic fluid delivery system
EP3137272C0 (en)	2023-11-15	MORTAR DISTRIBUTION SYSTEM
LT3188717T (lt)	2020-03-25	Vaisto forma, apimanti daleles
EP3212173A4 (en)	2018-06-20	Delivery systems
EP3018745B8 (en)	2017-05-10	Fuel cell system
HK1243340A1 (zh)	2018-07-13	透細胞質膜的傳遞
PT3136841T (pt)	2022-06-20	Sistemas de fermentação
GB201410270D0 (en)	2014-07-23	Cell delivery system and method
EP3101722A4 (en)	2016-12-21	FUEL CELL SYSTEM
EP3214685A4 (en)	2017-09-06	Fuel cell system
SG11201700043XA (en)	2017-02-27	Fuel cell system
GB201419607D0 (en)	2014-12-17	Fuel delivery system
EP3166671A4 (en)	2018-03-28	Metal-organic framework materials in gases delivery systems
SG11201607368XA (en)	2016-10-28	Vaccine delivery systems using yeast cell wall particles
EP3214687A4 (en)	2017-09-06	Fuel cell system
AU2015225914B2 (en)	2020-01-30	Microneedle based cell delivery
ZA201608085B (en)	2018-05-30	Grout delivery
IL252972A0 (en)	2017-08-31	Antigen delivery system
EP3174145A4 (en)	2017-06-07	Fuel cell system
GB2533265B (en)	2021-09-15	Fuel cell system
EP3109932A4 (en)	2016-12-28	FUEL CELL SYSTEM
IL247106A0 (en)	2016-09-29	Material delivery system
EP3161101A4 (en)	2017-12-20	Proppant-based chemical delivery system
EP3118922A4 (en)	2017-01-18	Fuel cell system
GB2539606B (en)	2021-11-24	Fuel cell system